We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
-2.03%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$2.48B
AUM Growth
-$380M
Cap. Flow
-$210M
Cap. Flow %
-8.45%
Top 10 Hldgs %
29.58%
Holding
106
New
13
Increased
24
Reduced
44
Closed
23
Avg Time Held
1 year
Top 10 Avg Time Held
0.2 years
Top 20 Avg Time Held
0.4 years

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$67.1M
2
CI icon
Cigna
CI
+$59.2M
3
UNH icon
UnitedHealth
UNH
+$55.2M
4
HUM icon
Humana
HUM
+$51.8M
5
ITCI icon
Intra-Cellular Therapies Inc.
ITCI
+$46.7M

Top Sells

Rank Stock Value
1
GEHC icon
GE HealthCare
GEHC
+$84.9M
2
ABBV icon
AbbVie
ABBV
+$69.8M
3
BIO icon
Bio-Rad Laboratories Class A
BIO
+$57.9M
4
COR icon
Cencora
COR
+$57.7M
5
ARGX icon
argenx
ARGX
+$50.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Miscellaneous 0%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BSX icon
1
Boston Scientific
BSX
$64B
$109M 4.39%
2,065,800
+1,280,100
+163% +$67.1M
2022 Q1
6 quarters
JAZZ icon
2
Jazz Pharmaceuticals
JAZZ
$13.9B
$103M 4.16%
797,500
+94,722
+13% +$12.6M
2022 Q2
5 quarters
BDX icon
3
Becton Dickinson
BDX
$52.8B
$74.1M 2.99%
286,800
-111,250
-28% -$30.1M
2023 Q1
2 quarters
NBIX icon
4
Neurocrine Biosciences
NBIX
$13.9B
$73.4M 2.95%
652,100
-13,216
-2% -$1.39M
2020 Q4
11 quarters
MCK icon
5
McKesson
MCK
$116B
$72.3M 2.91%
166,300
+65,100
+64% +$27.4M
2023 Q2
1 quarter
LEGN icon
6
Legend Biotech
LEGN
$3.85B
$65M 2.62%
967,000
+168,100
+21% +$11.7M
2022 Q4
3 quarters
THC icon
7
Tenet Healthcare
THC
$22.2B
$63.5M 2.56%
963,800
-26,700
-3% -$2M
2022 Q4
3 quarters
CI icon
8
Cigna
CI
$79B
$59.4M 2.39%
+207,700
New +$59.2M
2023 Q3
0 quarters
IDYA icon
9
IDEAYA Biosciences
IDYA
$3.27B
$57.9M 2.33%
2,144,971
-840,729
-28% -$21.3M
2021 Q1
10 quarters
UNH icon
10
UnitedHealth
UNH
$365B
$56.6M 2.28%
+112,200
New +$55.2M
2023 Q3
0 quarters
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.88B
$54.5M 2.2%
450,000
+152,500
+51% +$17.2M
2022 Q3
4 quarters
HUM icon
12
Humana
HUM
$51.9B
$53.7M 2.16%
+110,300
New +$51.8M
2023 Q3
0 quarters
ARVN icon
13
Arvinas
ARVN
$468M
$51.4M 2.07%
2,614,960
-158,229
-6% -$3.88M
2020 Q2
13 quarters
ACHC icon
14
Acadia Healthcare
ACHC
$2.89B
$50.3M 2.02%
715,000
+165,000
+30% +$12.3M
2022 Q2
5 quarters
KRTX icon
15
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$48.5M 1.95%
286,700
-155,500
-35% -$29.2M
2022 Q2
5 quarters
REGN icon
16
Regeneron Pharmaceuticals
REGN
$82B
$47.7M 1.92%
58,000
+33,200
+134% +$26.1M
2023 Q1
2 quarters
ZTS icon
17
Zoetis
ZTS
$32.4B
$45.6M 1.84%
262,100
+45,100
+21% +$8.19M
2023 Q1
2 quarters
IMVT icon
18
Immunovant
IMVT
$5.68B
$45.1M 1.81%
1,173,662
-911,338
-44% -$20.6M
2023 Q1
2 quarters
MLTX icon
19
MoonLake Immunotherapeutics
MLTX
$873M
$44.3M 1.78%
777,172
+377,172
+94% +$20.8M
2023 Q2
1 quarter
DHR icon
20
Danaher
DHR
$163B
$43.8M 1.76%
+199,205
New +$44.4M
2023 Q3
0 quarters
ZNTL icon
21
Zentalis Pharmaceuticals
ZNTL
$212M
$42.1M 1.7%
2,100,000
-234,000
-10% -$5.94M
2020 Q2
13 quarters
ITCI icon
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$41.7M 1.68%
+801,100
New +$46.7M
2023 Q3
0 quarters
SNDX icon
23
Syndax Pharmaceuticals
SNDX
$1.22B
$41M 1.65%
2,821,000
-51,000
-2% -$965K
2020 Q2
13 quarters
LLY icon
24
Eli Lilly
LLY
$1.12T
$40.3M 1.62%
75,000
-58,000
-44% -$29.9M
2023 Q2
1 quarter
NTRA icon
25
Natera
NTRA
$58.3B
$39.8M 1.6%
899,000
+466,100
+108% +$23.8M
2020 Q3
12 quarters
1
2 3 4 5

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Avidity Partners Management's Q3 2023 Portfolio in Review

As of Q3 2023, Avidity Partners Management held 106 positions worth $2.48B, down 13% from $2.86B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Avidity Partners Management withdrew a net $210M in Q3 2023, closing 23 positions and reducing 44 holdings. Its most notable exit was GE HealthCare, an estimated $84.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Avidity Partners Management opened a new position in Cigna worth $59.4M.

  • Avidity Partners Management's largest Q3 2023 buy was Cigna: 207,700 shares worth $59.4M.
  • Avidity Partners Management added most to Boston Scientific in Q3 2023, an estimated $67.1M increase.
  • Avidity Partners Management's biggest Q3 2023 reduction was argenx, cutting an estimated $50.7M.
  • Avidity Partners Management fully exited GE HealthCare in Q3 2023, selling an estimated $84.9M.
  • Avidity Partners Management's ten largest holdings make up 30% of its $2.48B portfolio in Q3 2023.
  • Avidity Partners Management opened 13 new positions and closed 23 in Q3 2023.
  • Avidity Partners Management's portfolio value fell 13% quarter-over-quarter to $2.48B.

Based on Avidity Partners Management's 13F filing for Q3 2023, filed 14 Nov 2023.